Atria Wealth Solutions’s Zomedica Corp. ZOM Stock Holding History

Atria Wealth Solutions’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$1.63K	–	1976
2022 Q4	$1.63K	Hold	10,000	–	–	﹤0.01%	1795
2022 Q3	$2.11K	Sell	10,000 -15,199	-60%	-$4.02K	﹤0.01%	1739
2022 Q2	$5K	Buy	25,199 +15,199	+152%	+$3.87K	﹤0.01%	1626
2022 Q1	$3K	Buy	+10,000	New	+$3.27K	﹤0.01%	1723

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $67.5B AUM 28.09% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PWMG

Pinnacle Wealth Management Group Plymouth, Michigan $214M AUM 20.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Atria Wealth Solutions's ZOM Position: Q1 2023 in Review

Atria Wealth Solutions sold out of Zomedica Corp. (ZOM) in Q1 2023, closing a stake of 10,000 shares — an estimated $1.63K sold.

Atria Wealth Solutions first reported a position in ZOM in Q1 2022 and held it in 4 quarters. The position peaked at $5K in Q2 2022. 90 funds tracked by Wall St. Rank hold ZOM as of Q1 2023.

Atria Wealth Solutions reported no remaining Zomedica Corp. position as of Q1 2023 after selling out during the quarter.
Atria Wealth Solutions sold 10,000 Zomedica Corp. shares in Q1 2023, an estimated $1.63K.
Atria Wealth Solutions first reported a position in Zomedica Corp. in Q1 2022 and held it in 4 quarters.
Atria Wealth Solutions's Zomedica Corp. position peaked at $5K in Q2 2022.
90 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2023.

Based on Atria Wealth Solutions's 13F filing for Q1 2023, filed 10 May 2023.